HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CARU Recommends Building Guardrails Around Children’s Advertising In Metaverse

Executive Summary

BBB National Programs’ Children’s Advertising Review Unit outlines best practices for advertising to kids in the metaverse without running afoul of its guidance or US FTC rules.

You may also be interested in...



Beauty In Gaming: A New Marketing Frontier With A Captive (And Increasingly Female) Audience

Per Lisa Hau, Bidstack’s chief strategy officer, “Gaming has an audience that is undeniable. It reaches one-third of the world's population and continues to grow.” And the average gamer is not the popularly imagined anti-social teenage male, as “45% of gamers are now female, and the average age sits comfortably at 34 years old.” It’s a compelling opportunity for beauty brands, Bidstack says.

Metaverse May Be ‘Blurry,’ But Expectations For Advertising To Children Are Not – CARU

The Children’s Advertising Review Unit of the BBB National Programs Inc. tells marketers its guidelines apply to ads in the metaverse, and the watchdog will ‘strictly enforce’ in the space.

Unilever Squelches Dr. Squatch Comparative Claims In NAD Forum; Advertiser Can Keep Its 'Sh*t List’

Dr. Squatch was able to substantiate that it uses “no harmful ingredients” as well as certain claims about avoiding a “Sh*t list” of ingredients, but agreed to modify other claims the National Advertising Division deemed falsely disparage competitor products, such as Unilever’s Dove personal-care brand.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel